Having trouble accessing articles? Reset your cache.

Pharming, Santarus deal

Santarus received exclusive rights to commercialize Pharming's Rhucin in North America. The recombinant human complement 1 esterase inhibitor ( rhC1INH) is known

Read the full 220 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE